Mother reveals 'miracle drug' halts ALS progression

Raziel Green, a 52-year-old mother from New Jersey, has been living with a rare type of ALS since 2017. After years of struggling with symptoms like heavy legs and balance issues, she sought further medical opinions. Eventually, she was diagnosed with a genetic form of ALS caused by mutations in the SOD1 gene. Green joined a clinical trial for a new medication called QALSODY, developed by Biogen. This drug is given through a lumbar puncture and aims to reduce the harmful effects of the SOD1 mutation. Green has experienced significant benefits from the treatment; her condition has not worsened since she started the trial nearly eight years ago. Medical experts say that about 20% to 25% of patients with SOD1-ALS who take QALSODY have seen not only slowed progression of the disease but also signs of improvement. Although some patients faced side effects, Green's experience has been largely positive. She reports being able to participate in her children's activities and maintain some independence. QALSODY was recently approved by the U.S. FDA, making it accessible for patients diagnosed with this specific genetic mutation. Green hopes to continue enjoying life and stay stable with the help of this "miracle drug." She also emphasizes the importance of potential preventative treatment for her children.